No products in the cart.
Pre-made Pembrolizumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-435
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pembrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
| Products Name (INN Index) | Pre-Made Pembrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
|---|---|
| INN Name | Pembrolizumab |
| Target | PDCD1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Aduro BioTech,AIO Studien gGmbH,Amgen,Augusta University,Bayer,BerGenBio,Big Ten Cancer Research Consortium,BioLineRx,Canadian Cancer Trials Group,Celgene Corporation,Columbia University,Dana-Farber |
| Conditions Approved | Cervical cancer,Colorectal cancer,Diffuse large B cell lymphoma,Gastric cancer,Head and neck cancer,Hodgkin's disease,Liver cancer,Malignant melanoma,Non-small cell lung cancer,Pancreatic cancer,Soli |
| Conditions Active | Small cell lung cancer,Bladder cancer,Breast cancer,Endometrial cancer,Fallopian tube cancer,Gastrointestinal cancer,Mesothelioma,Multiple myeloma,Nasopharyngeal cancer,Oesophageal cancer,Ovarian can |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | Lambrolizumab |
| Gm Offical Target Name | PDCD1 |
| Package |
Previous slide
Next slide
